GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational ...

GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

The clinical trial success of bepirovirsen, which will be submitted to regulatory agencies for approval, could be a boon for ...

Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

GSK (LSE:GSK) has been drawing investor attention after recent share price moves and updated return figures, prompting a ...